ABT-199
CAS No. 1257044-40-8
ABT-199 ( GDC-0199 )
Catalog No. M11056 CAS No. 1257044-40-8
Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 43 | In Stock |
|
10MG | 61 | In Stock |
|
25MG | 75 | In Stock |
|
50MG | 80 | In Stock |
|
100MG | 104 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameABT-199
-
NoteResearch use only, not for human use.
-
Brief DescriptionVenetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays.
-
DescriptionVenetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.
-
SynonymsGDC-0199
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorMcl-1; Bcl-2; Bcl-w; Bcl-xL
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1257044-40-8
-
Formula Weight868.44
-
Molecular FormulaC45H50ClN7O7S
-
Purity>98%(HPLC)
-
SolubilityDMSO: 100 mg/mL warmed (115.14 mM)
-
SMILESO=C(NS(=O)(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC5=C(C6=CC=C(Cl)C=C6)CC(C)(C)CC5)CC4)C=C3OC7=CN=C(NC=C8)C8=C7
-
Chemical Name4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Souers AJ, et al. Nat Med, 2013, 19(2), 202-208.
molnova catalog
related products
-
AZD 5991
AZD 5991 (AZD5991) is a potent and selective macrocyclic inhibitor of Mcl-1 with sub-nanomolar affinity.
-
S55746
S55746 (BCL201, Servier-1) is a novel potent, selective, orally bioavailable inhibitor of BCL-2 with Ki of 1.3 nM.
-
BCL6-IN-8
BCL6-IN-8 (BCL6-i) is a potent, irreversible and cell-active BCL6 inhibitor with inact/KI value of 1.9 × 104 M-1 s-1, targets Cys53 located at the protein-protein interaction interface.